Neoleukin Therapeutics, Inc. (NLTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NLTX Stock Price Chart Interactive Chart >
NLTX Price/Volume Stats
|Current price||$0.60||52-week high||$3.84|
|Prev. close||$0.58||52-week low||$0.38|
|Day high||$0.60||Avg. volume||133,816|
|50-day MA||$0.49||Dividend yield||N/A|
|200-day MA||$0.84||Market Cap||25.34M|
Neoleukin Therapeutics, Inc. (NLTX) Company Bio
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops medicines to treat serious diseases, including cancer, inflammatory, and autoimmune disorders.
Most Popular Stories View All
NLTX Latest News Stream
|Loading, please wait...|
NLTX Latest Social Stream
View Full NLTX Social Stream
Latest NLTX News From Around the Web
Below are the latest news stories about NEOLEUKIN THERAPEUTICS INC that investors may wish to consider to help them evaluate NLTX as an investment opportunity.
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cellsSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells. The data are bein
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.
In a report released today, Mara Goldstein from Mizuho Securities downgraded Neoleukin Therapeutics (NLTX - Research Report) to a Hold, with a price target of $2.00. The company's shares closed yesterday at $0.53.Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics. According to TipRanks, Goldstein has an average return of 1.1% and a 36.65% success rate on recommended stocks. Neoleukin Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.00.
Neoleukin Therapeutics Inc (NASDAQ: NLTX) announced discontinuing the development of NL-201 for strategic reasons. Preliminary monotherapy data from the Phase 1 study of NL-201 did not demonstrate significant immunogenicity even after multiple cycles of therapy. The data demonstrated engagement of the target receptor's expected pharmacodynamic changes for a potent IL-2/IL-15 agonist. In April, the FDA removed the clinical hold related to Neoleukin's investigational new drug application to begin
-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 -- SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended
NLTX Price Returns